Daily Endocrinology Research Analysis
Three impactful endocrinology papers span mechanistic, prognostic, and comparative-effectiveness research. A Cell Reports Medicine study identifies PGK1 as a dual-mode driver of diabetic kidney disease and reports small-molecule antagonists. TrialNet data in Diabetes Care delineate age-specific progression patterns to type 1 diabetes, and a meta-analysis shows GLP-1 receptor agonists improve kidney outcomes vs DPP4i/sulfonylureas/insulin but are inferior to SGLT2 inhibitors.
Summary
Three impactful endocrinology papers span mechanistic, prognostic, and comparative-effectiveness research. A Cell Reports Medicine study identifies PGK1 as a dual-mode driver of diabetic kidney disease and reports small-molecule antagonists. TrialNet data in Diabetes Care delineate age-specific progression patterns to type 1 diabetes, and a meta-analysis shows GLP-1 receptor agonists improve kidney outcomes vs DPP4i/sulfonylureas/insulin but are inferior to SGLT2 inhibitors.
Research Themes
- Diabetic kidney disease mechanisms and therapeutic targets
- Age-specific progression and staging in type 1 diabetes
- Comparative kidney outcomes of incretin-based therapies versus SGLT2 inhibitors
Selected Articles
1. Phosphoglycerate kinase 1 contributes to diabetic kidney disease through enzyme-dependent and independent manners.
This mechanistic study identifies PGK1 as a central driver of DKD via dual modes: enzymatic 3-PG–GPX1–NLRP3 activation and non-enzymatic Aldh1l1–UNC5CL inflammation. Genetic manipulation in renal tubules and small-molecule antagonists (including an FDA-approved drug) ameliorated DKD in models, nominating PGK1 as a druggable target.
Impact: It uncovers a novel, targetable metabolic–inflammatory axis in DKD and provides immediate translational leads (three antagonists) that prevented DKD in vivo.
Clinical Implications: PGK1 inhibition could complement current DKD therapies by targeting tubular metabolic–inflammasome pathways. Repurposing oxantel pamoate warrants early-phase clinical testing with biomarkers (3-PG, inflammasome readouts).
Key Findings
- PGK1 is upregulated in DKD patients and mice; tubular PGK1 knockout mitigates DKD, while overexpression worsens it.
- Enzymatic 3-PG production inhibits GPX1, activating NLRP3 inflammasome; non-enzymatic PGK1 binds Aldh1l1 to promote UNC5CL-mediated inflammation.
- PAX5 drives PGK1 upregulation in DKD; small-molecule antagonists (C-16, lirinidine, oxantel pamoate) prevent DKD in models.
Methodological Strengths
- Integrated human and mouse evidence with metabolomics, genetics, and pharmacology
- Cell type–specific manipulation of PGK1 in renal tubules with in vivo phenotyping
Limitations
- Preclinical study; no human interventional data
- Potential off-target effects and long-term safety of antagonists remain unknown
Future Directions: Phase 1/2 trials of oxantel pamoate with tubular injury and inflammasome biomarkers; medicinal chemistry to optimize PGK1-selective antagonists; patient stratification by PGK1/PAX5/3-PG signatures.
Diabetic kidney disease (DKD) is characterized by abnormal metabolic profiles. Metabolomics reveals increased serum levels of 3-phosphoglycerate (3-PG) in DKD patients. The protein expression of phosphoglycerate kinase 1 (PGK1), a key rate-limiting enzyme for 3-PG synthesis, is concomitantly upregulated in DKD patients and mice. The development of DKD is significantly mitigated by renal tubular epithelial cell-specific knockout of PGK1 and robustly worsened by PGK1 overexpression. Mechanistically, PGK1-dependent enzymatic production of 3-PG facilitates DKD through inhibiting GPX1 to activate the NLRP3 inflammasome. PGK1 promotes UNC5CL-mediated inflammation by binding to aldehyde dehydrogenase-1 L1 (Aldh1l1) through its non-enzymatic activity. The transcription factor paired box protein 5 (PAX5) mediates the upregulation of PGK1 in DKD. High-throughput screening reveals that C-16 from ChemDiv, the natural product lirinidine, and the Food and Drug Administration (FDA)-approved oxantel pamoate are potent PGK1 antagonists and efficaciously prevent DKD. Overall, blocking PGK1 may be a promising avenue for DKD management.
2. Contrasting Adult and Pediatric Populations in a Cohort of At-Risk Relatives in The T1D TrialNet Pathway to Prevention Study.
Among at-risk relatives, adults more often have single autoantibody and slower progression at stage 1, but stage 2 progression matches children (≈78% at 5 years). Adults progressing from single GAD positivity show distinct genetic risk profiles, and HbA1c/risk indices better identify adult progressors.
Impact: These findings support age-tailored monitoring: adults with stage 2 require intensive follow-up similar to children, whereas earlier stages may allow less frequent surveillance.
Clinical Implications: Screening programs should stratify by age and stage: prioritize rapid follow-up and trial enrollment for adults with stage 2 T1D; use HbA1c/metabolic risk scores for adult progression prediction; educate that single GAD positivity in adults is not benign.
Key Findings
- Adults had more single autoantibody positivity (4.0% vs 2.6%) and less multiple autoantibodies (0.83% vs 2.8%).
- Five-year progression risk was lower in adults at single autoantibody and stage 1 (8.2% and 17%) but identical at stage 2 (78%).
- Adult progressors were more often single GAD-positive with lower T1D but higher T2D genetic risk; HbA1c/risk indices performed better in adults.
Methodological Strengths
- Very large multicenter cohort with standardized staging and comparisons across age groups
- Evaluation of genetic risk scores and metabolic indices alongside autoantibody profiles
Limitations
- Observational design with potential selection bias (family-based screening)
- Follow-up intervals and timing heterogeneity; generalizability beyond relatives uncertain
Future Directions: Prospective age-tailored surveillance algorithms; interventional trials targeting stage 2 in adults; refine risk scores integrating genetics, HbA1c, and autoantibodies.
OBJECTIVE: More than half of incident type 1 diabetes (T1D) occurs in adults, yet research on disease progression predominantly focuses on at-risk children. We compared autoantibody screening outcomes and T1D progression in adults versus children. RESEARCH DESIGN AND METHODS: We studied 135,914 children (aged <18 years) and 99,795 adult relatives of individuals with T1D screened in the TrialNet Pathway to Prevention study. In autoantibody positive participants, we compared progression rates, associations with risk factors, and performance of metabolic risk scores. RESULTS: Adults were more likely than children to screen positive for a single autoantibody (4.0% vs. 2.6%) but less likely for multiple autoantibodies (0.83% vs. 2.8%; P < 0.001). Progression to stage 3 disease was lower in adults with single autoantibody positivity or stage 1 T1D than in children (5-year risks: single autoantibody, adults 8.2% vs. children 22%, P < 0.001; stage 1, adults 17% vs. children 47%, P < 0.001). However, adults with stage 2 T1D at initial staging oral glucose tolerance test had comparable 5-year progression risks to children (78% for both groups). A higher proportion of adults progressing to clinical diabetes were single autoantibody positive (40% vs. 15%; P < 0.0001); these individuals commonly had single glutamic acid decarboxylase positivity and had lower type 1 but higher type 2 genetic risk scores compared with multiple autoantibody positive adults. HbA1c and established risk indices more effectively identified progressors in adults compared with children. CONCLUSIONS: Autoantibody positive adult relatives have distinct autoantibody trajectories and progression risks compared with children, suggesting the need for tailored monitoring and intervention strategies.
3. Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists Versus Other Glucose-Lowering Agents in People With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Data.
Across 31 observational studies (n≈1.6M), GLP-1 RAs yielded better kidney outcomes than DPP4 inhibitors, sulfonylureas, and basal insulin but were inferior to SGLT2 inhibitors for AKI, kidney-related hospitalizations, and ≥40% eGFR decline. Effects on ≥50% eGFR decline and ESKD were similar to SGLT2 inhibitors.
Impact: Provides comparative-effectiveness evidence to guide agent selection in T2D with kidney risk, reinforcing SGLT2 inhibitors as first-line for renal protection and positioning GLP-1 RAs as preferable to DPP4i/sulfonylureas/insulin when SGLT2i are unsuitable.
Clinical Implications: Prefer SGLT2 inhibitors for renal protection when possible; if contraindicated, GLP-1 RAs may confer renal benefit over DPP4i/sulfonylureas/insulin. Monitor AKI risk and hospitalization, especially when GLP-1 RAs are used instead of SGLT2 inhibitors.
Key Findings
- Versus SGLT2 inhibitors, GLP-1 RAs were associated with higher AKI (HR 1.12), kidney-related hospitalizations (HR 1.66), and ≥40% eGFR decline (HR 1.40).
- Versus DPP4 inhibitors, GLP-1 RAs reduced ≥50% eGFR decline (HR 0.84), kidney-related hospitalizations (HR 0.73), and ESKD (HR 0.70).
- Benefits similar when compared to sulfonylureas; versus basal insulin, GLP-1 RAs reduced albuminuria progression (HR 0.89).
Methodological Strengths
- Large-scale synthesis with multiple active comparators; PROSPERO-registered protocol
- Random-effects models and hazard ratio pooling across 31 observational cohorts
Limitations
- Observational data subject to confounding by indication and residual bias
- High heterogeneity across studies; outcome definitions and adjustment sets vary
Future Directions: Head-to-head pragmatic trials and target trial emulation comparing GLP-1 RAs vs SGLT2 inhibitors for renal endpoints; subgroup analyses in CKD stages and albuminuria strata.
AIMS: Randomized placebo-controlled clinical trials showed that glucagon-like peptide-1 receptor agonists (GLP-1 RA) reduce kidney risk in patients with type 2 diabetes (T2D), prominently in those with chronic kidney disease. It is unclear whether these findings may apply to broader populations of patients with T2D treated in real-world settings and compared to active controls. We summarised real-world data of adverse kidney outcomes among patients with T2D initiating GLP-1 RA versus other glucose-lowering agents. MATERIALS AND METHODS: We searched PubMed and Embase for observational cohort studies (April 2005-January 2025; PROSPERO CRD42023405356). Initiators of GLP-1 RA were compared to sodium-glucose cotransporter-2 inhibitors (SGLT2i), dipeptidyl-peptidase 4 inhibitors (DPP4i), sulfonylureas, or basal insulin. Outcomes included risks of albuminuria progression, ≥ 40 or ≥ 50% eGFR reduction from baseline, acute kidney injury (AKI), kidney-related hospitalizations, and end-stage kidney disease (ESKD), per data availability. We synthesised the data using inverse variance-weighted averages of logarithmic hazard ratios (HR)s in random-effect models. RESULTS: Thirty-one studies were eligible, encompassing 1,601,389 patients (mean age 49-78 years, 5%-64% women), with 21, 6, 5, and 1 of them using SGLT2i, DPP4i, basal insulin, and sulfonylureas as a comparator, respectively. Compared with SGLT2i, GLP-1 RA initiators had higher risks for AKI (HR [95% CI] 1.12 [1.05-1.20]), kidney-related hospitalizations (1.66 [1.01-2.73]), and ≥ 40% reduction in eGFR (1.40 [1.27-1.53]), without evidence for differences in risks of ≥ 50% eGFR reduction or ESKD. Compared to DPP4i, GLP-1 RA initiators had lower risks for experiencing ≥ 50% eGFR reduction (0.84 [0.76-0.92]), kidney-related hospitalizations (0.73 [0.65-0.83]), and ESKD (0.70 [0.63-0.78]). Similar benefits were observed when comparing GLP-1 RA to sulfonylureas. Compared to basal insulin, GLP-1 RA initiation was associated with a lower risk of albuminuria progression (0.89 [0.80-0.99]), with inconsistent data regarding possible benefits in reducing ESKD risk. CONCLUSIONS: In patients with T2D, initiation of GLP-1 RA in real-world settings may be associated with improved kidney outcomes compared to DPP4i, sulfonylureas, and basal insulin, and worse kidney outcomes compared to SGLT2i.